Why Nanobiotix S.A.’s (NBTX) Stock Is Down 6.26%
As of Thursday, July 16, Nanobiotix S.A.’s NBTX share price has dipped by 6.26%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Commentary & Analysis
Why Nanobiotix S.A.’s (NBTX) Stock Is Down 5.14%
As of Wednesday, July 15, Nanobiotix S.A.’s NBTX share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Nanobiotix S.A.’s (NBTX) Stock Is Up 7.08%
As of Tuesday, July 14, Nanobiotix S.A.’s NBTX share price has surged by 7.08%, which has investors questioning if this is right time to sell.Michael Rose
Why Nanobiotix S.A.’s (NBTX) Stock Is Down 6.33%
As of Tuesday, July 07, Nanobiotix S.A.’s NBTX share price has dipped by 6.33%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Nanobiotix S.A.’s (NBTX) Stock Is Up 6.22%
As of Monday, July 06, Nanobiotix S.A.’s NBTX share price has surged by 6.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | NBTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,685.4 | $257.9 | 52% |
|
| Shares Out (Mil) | 56.0 | 54.3 | 50% |
|
| Institutional Ownership | 79.0% | 92.9% | 48% |
|
| Float (Mil) | 35.6 | 41.4 | 39% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 131 | 674 | 37% |
|
| Price Change (52-week) |
102.6% | 51.5% | 94% |
|
| Growth | NBTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 68.7% | 13.2% | 97% |
|
| Net Income (5yr) | 7.3% | (10.1%) | 51% |
|
| EPS (5yr) | 19.0% | 15.8% | 67 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (55.5%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NBTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $13 | $37 | 10% |
|
| Net Income (TTM) (Mil) | ($60) | ($43) | 15% |
|
| EPS (TTM) | ($1.262) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($39) | ($32) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $95 | $2 | 76% |
|
| Long-Term Debt (Q1) (Mil) | $85 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $1,617 | $174 | 46% |
|
| Valuation | NBTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.51 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NBTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 68.9% | 96% |
|
| Net Margin | (459.5%) | (72.5%) | 2% |
|
| ROA | (60.5%) | (47.7%) | 10% |
|
| ROE | 101.4% | (54.9%) | 96% |
|
| Liabilities to Assets | 126.0% | 29.1% | 97% |
|
| F-Score | 3 | 3 | 18% |
|
Nanobiotix S.A. did not pass any screens on 9/25/2026.
